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General Summary 
The immune system comprises a complex network of specialized cells and organs that 
function together to recognize and remove potentially harmful "non-self", i.e. pathogens, 
malignant cells and –by extension– also transplanted allogeneic cells. 
Innate –evolutionary ‘old’ – immune mechanisms function in a non-clonal germline-
encoded manner, whereas the hallmark of the adaptive immune system is clonal 
expansion of cells after rearrangement of germline-encoded immune receptors. 
Natural killer cells (NK cells) represent an important component of the innate immune 
system, whereas CD4+ (‘helper’) and CD8+ (‘cytotoxic’) T cells are key players of 
adaptive immunity. 
Rare NK cell-deficient humans suffer from overwhelming herpes viral infections, 
indicative of their important role in infection biology.  Mechanistic insight into their anti-
viral effector function, however, remains largely based on murine data.  Intriguingly, the 
best molecular understanding of NK cell function in humans is derived from studies of 
the ‘man-made’ setting of allo-stem cell transplantation.  By contrast, in solid organ 
transplantation NK cells have, until the recent emergence of exciting murine data, been 
largely ignored. 
To begin to understand the role NK cells may play in human solid organ transplantation, 
we initiated a prospective cohort-study of kidney allo-transplant recipients. 
Blocking the IL-2 receptor α-chain (CD25) with mAb is an immunomodulatory treatment 
modality used in various clinical situations, including allo-transplantation.  Of note, in 
patients with multiple sclerosis and uveitis administration of anti-CD25 mAb has been 
linked to robust expansion of CD56bright NK cells, which has been suggested to mediate 
its effect.  On this background we first we enumerated NK cell-subsets in kidney 
transplant-recipients receiving anti-CD25 mAb (n=16) before transplantation, and at 
week 12, 26 and 52 post-transplantation, and in healthy controls (n=5).  In healthy 
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controls NK cell-subsets remained stable over time.  In transplant-recipients, by 
contrast, overall median frequencies of both CD56bright and CD56dim NK cells transiently 
decreased after transplantation.  Expansion of CD56bright NK cells was observed in only 
6/16 patients.  These data dissociate expansion of CD56bright NK cells and in vivo 
blockade of CD25 in kidney allograft recipients, thus dismissing expansion of CD56bright 
NK cells as unifying clinical hallmark of its effect across all clinical situations               
(G. Zenhaeusern et al. Submitted). 
Aiming next at studying functional allo-specific properties of NK cells, we developed a 
simple, paraformaldehyde fixation-based protocol that provided an accurate and robust 
means for assessing alloreactivity, avoiding an irradiation-induced network of various 
cytokines complicating interpretation of results (G. Zenhaeusern et al. JIM ‘07).  Using 
this protocol, we found that a subset of NK cells was activated rather than silenced 
when interacting with cells expressing normal levels of autologous MHC I.  Instead of 
inducing an inflammatory phenotype, however, activation led to the secretion of the 
regulatory cytokines TGF-β and IL-10.  Together these data ascribe a novel pattern of 
reactivity to NK cells with potential implications both in autologous and allogeneic 
systems (G. Zenhaeusern et al. in revision). 
 
The molecular understanding of the various cellular interactions involving NK cells is 
only emerging, whereas recognition by T cell receptor (TCR) of cognate antigen 
presented by HLA molecules has been analyzed in depth.  On the other hand, relatively 
little attention has been given to basic T cell physiological properties, such as their 
random crawling activity (required to screen for antigen) or their mitochondrial energy 
efficiency.  In order to begin to tackle these important issues, I established an 
experimental in vitro system allowing us to quantify random crawling activity of various T 
cell subsets, and monitor crawling under conditions mimicking the intra- and 
extravascular environment.  Using these assays, we identified robust differences 
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between phenotypically distinct subsets of CD8+ T cells with regards to their random 
movement activity and the frequency-distribution of crawling cells.  Specifically, using 
migration-assays and time-lapse microscopy we found (i) that CD8+ T cells lacking the 
lymph node homing receptors CCR7 and CD62L migrated more efficiently in trans-well 
assays and (ii) that these same cells were characterized by a high frequency of cells 
exhibiting random crawling activity under culture conditions mimicking the 
interstitial/extravascular milieu –but not when examined on endothelial cells. 
With this finding at hand, we hypothesized that increased random movement activity 
ought to be linked to higher energy consumption.  To test this hypothesis we measured 
mRNA expression of genes key to mitochondrial energy metabolism (PGC-1β, ERRα, 
Cytochrome C, ATP Synthase, and the uncoupling proteins UCP-2 and UCP-3), 
quantified cellular ATP contents and performed micro-calorimetric analyses.  Much to 
our surprise, ATP contents were consistently higher in CCR7+ CD8+ T cells, the subset 
of T cells that showed less crawling activity, and genes involved in mitochondrial 
biosynthesis and ATP production (PGC-1β, ERRα, Cytochrome C, ATP Synthase) were 
significantly upregulated.  Intriguingly, we also observed that these CCR7+ CD8+ T 
cells expressed uncoupling proteins UCP-2 and UCP-3 at significantly higher levels 
than CCR7- CD8+ T cells, which at least partly explained the higher heat flow measured 
in the lymph node homing T cell subset. (G. Zenhaeusern et al. Blood 2008, e-pub 
ahead print).  Together these assays identified a phenotypically distinct ‘high crawling-
frequency’ CD8+ T cell population, and differentially regulated heat production among 
non-lymphoid vs. lymphoid homing CD8+ T cells. 
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Introduction 
The human immune system has evolved to protect us from harmful ‘non-self’.  The first 
line of immunological defence is provided by the innate immune system, consisting of 
physical and chemical barriers, the complement system, phagocytic cells, and a 
lymphocyte subset termed natural killer cells (NK cells).  The adaptive immune system 
is composed of T cells, including CD4+ helper T cells and CD8+ cytotoxic T cells, as 
well as B cells that can be activated to develop into antibody secreting plasma cells. 
During an infection, NK cells become activated via germline-encoded receptors to 
directly kill infected cells and/or secrete inflammatory cytokines.  T and B cells, by 
contrast, recognize cognate antigen presented by HLA molecules via receptors 
generated by somatic recombination. 
NK cells  
Phenotypically NK cells can be defined as CD3 (TCR) negative, CD56 (neural cell 
adhesion molecule) positive lymphocytes.  Based on their expression-level of CD56 and 
CD16 (FcγRIII), NK cells can be divided into two subsets.  Approximately 90% of all 
circulating NK cells express low levels of CD56 and CD16 (so-called CD56dim NK 
cells).1,2  CD56dim NK cells store granules containing perforin and granzyme, and are 
able to immediately kill virally infected cells and tumour cells (natural cytotoxicity).  
CD16 binds the Fc part of antibodies bound to target cells, mediating antibody-
dependent cellular cytotoxicity (ADCC).3,4  The remainder 10% of circulating NK cells 
expresses high levels of CD56 and are mostly CD16 negative (so-called CD56bright or 
regulatory NK cells).  CD56bright NK cells contain low levels of perforin and granzymes, 
but when activated can be induced to secrete large amounts of inflammatory and, to 
some extent, anti-inflammatory cytokines.2,5-8 
NK cell function is regulated by clonally distributed killer immunoglobulin-like receptors 
(KIR), natural killer cell receptors (NCRs) and NKG2D. KIR mediate either inhibitory or 
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activating signals, depending on their cytoplasmic tails.  Inhibitory KIR associate with an 
immunoreceptor tyrosine-based inhibition motif (ITIM), and recognize conserved motifs 
on HLA A, B, C or G molecules.9,10  Downregulation of HLA I molecules after viral 
infections or on tumour cells leads to a lack of inhibitory signals, and hence killing of 
target s ('missing self' recognition).11-15  By contrast, NCR, NKG2D and KIR that 
associate with an immunoreceptor tyrosine-based activation motif (ITAM) mediate 
activating signals.15-19 
The 'missing self' principle as outlined above for infected and malignantly transformed 
cells is also thought to underlie NK cell alloreactive killing: the HLA C locus is 
characterized by an asparagine/lysine polymorphism at position 80.  Each HLA C 
allotype is recognized by a distinct set of inhibitory KIR molecules.10,20,21  Absence of 
any of these two HLA C epitopes vis-à-vis a given NK cell leads to a lack of inhibition of 
the corresponding KIR expressed on this NK cell, and hence to its allospecific 
activation.  In hematological stem cell transplantation, such 'missing self' reactions –in 
the sense of NK cell-mediated graft versus leukemia effects from HLA C mismatched 
donors– have been demonstrated to exert powerful graft-versus-leukemia effects.22,23  
In haplo-identical hematopoietic transplantation, for instance, alloreactive NK cells were 
shown to reduce the risk for relapse.23 
The role NK cells play in solid organ transplantation remains largely unknown.  At the 
University Hospital Basel, standard immunosuppression for kidney transplant recipients 
consists of a calcineurin-inhibitor-based triple therapy plus induction-therapy with 
basiliximab (anti-CD25 mAb).  Anti-CD25 mAb targets the IL-2R α-chain expressed on 
activated T cells.  In patients suffering from auto-immune diseases –such as multiple 
sclerosis or uveitis– anti-CD25 mAb have also been used.  In these patients expansion 
of CD56bright NK cells –often termed regulatory NK cells and expressing CD25– has 
been documented.24,25  Against this background we aimed at enumerating and 
phenotyping circulating NK cells in renal transplant recipients before and after 
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transplantation and relating these data to infectious episodes, allograft rejection and 
transplant function. 
As stated, ligands for MHC I molecules actively 'silence' NK cell activity.  Inversely, NK 
cell activity is triggered vis-à-vis cells lacking expression of autologous MHC I, a 
situation encountered in allogeneic transplantation ('missing-self' recognition).  In mice, 
data of NK cells triggering an immune response in solid organ transplantation are 
emerging.  It has, for example, been shown that NK cells can mediate transplant 
tolerance via killing of graft-derived antigen presenting cells (APC), thus reducing the 
potential for alloreactive T cells to be induced.26  Besides their capacity to kill target 
cells, activated NK cells are able to produce various immunoregulatory cytokines.  In 
addition to the secretion of IFN-γ, monokine-stimulated NK cells are also capable of 
secreting cytokines such as TNF-α and TNF-β, IL-10, IL-13 and GM-CSF.2  Moreover, 
lymph-node homing NK cells have recently been shown to be able to secrete large 
amounts of IFN-γ early during the course of an immune response, hence contributing to 
TH1 polarization of T cells.27 
Here we aimed at reassessing the ex vivo response of NK cells vis-à-vis autologous 
and allogeneic target cells without prior stimulation.  While proliferation is still used as 
an indicator of alloreactivity –and is routinely performed– measuring the release of 
cytokines is more sensitive to detect allospecific lymphocyte activation.  Mixed 
lymphocyte reactions remain central to the characterization of cellular allo-interactions.  
We therefore sought to develop a protocol allowing us to measure –in a highly sensitive 
and specific manner– cytokine secretion induced in unprimed NK cells upon direct cell-
cell contact. 
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CD8+ T cells 
CD8+ T cells are crucial effectors of the adaptive immune system.  Upon activation, 
CD8+ T cells are able to secrete inflammatory/regulatory cytokines and, similarly to NK 
cells, kill target cells by the release of prestored perforin and granzymes. 
A central feature of the adaptive immune response is the generation of antigen-specific 
effector and memory T cells.  Naïve T cells are induced to proliferate (clonal expansion) 
and differentiate upon encounter with cognate antigen presented by MHC molecules 
and co-stimulatory signals provided e.g. by CD80 and CD86 on dendritic cells in 
secondary lymphoid structures.  Activation and subsequent differentiation lead to the 
formation of several CD8+ T-cell memory subsets with different functional and migratory 
properties, classified as central memory and effector memory cell subsets.28,29  Central 
memory cells recirculate between the blood and the lymphoid compartment and are 
thought to provide a pool of antigen-experienced cells with a high proliferative capacity 
but a lower activation threshold than naïve cells, thus allowing for a more rapid 
generation of effector cells during a recall response.30  In contrast, effector memory 
CD8+ T cells are thought to allow for a recall response in the tissue, as these cells 
survey nonlymphoid organs in search of cognate antigen.31,32 
Homing characteristics are thought to be controlled by the expression pattern of 
adhesion molecules and chemokine receptors acquired by specialized T cell subsets 
during the process of differentiation and polarization.  According to their phenotype –
which is linked to specific immunological functions– CD8+ T cells can be divided into T 
cell subsets with distinct migratory properties: naïve and central memory T cells co-
express the lymph node homing receptor CC chemokine receptor 7 (CCR7) and the 
adhesion molecule L-selectin (CD62L), whereas effector memory and terminally 
differentiated T cells lack expression of both these markers, and acquire receptors 
allowing homing to peripheral tissue and to sites of infection/inflammation, 
respectively.28,29,33,34 
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T cells move randomly, a feature that has been termed ‘random walk’.35-37  Such 
random lymphocyte motility allows T cells to encounter other cells of the immune 
system.  Lymphocyte motility (‘crawling’) relies on the binding of motor proteins to 
polarized cytoskeletal filaments, an ATP-consuming process.38  Typically T cells crawl in 
one direction by repeated extension and subsequent contraction of their cell-stoma, 
followed by pausing, in cycles of approximately 2 minutes.39,40  The energy for crawling 
is generated by oxidative phosphorylation. 
ATP synthase is the enzyme that catalyzes the conversion of ADP (adenosine 
diphosphate) and anorganic phosphate (Pi) to ATP making use of the proton gradient at 
the inner membrane of mitochondria.41  Uncoupling proteins (UCP-1 to 3) are 
mitochondrial anion transporters that reduce the proton gradient by diverting protons 
thus producing heat.  UCP-1 and UCP-3 are expressed mostly in skeletal muscles and 
brown fatty tissues,42-44 whereas UCP-2 is more widely expressed.45 
In our experiments, we first assessed the ex vivo migration of human CCR7- and 
CCR7+ CD8+ T cells on fibronectin and on HUVEC (human umbilical endothelial cells), 
mimicking intravascular and extravascular conditions in vitro respectively.  In order to 
shed light on the energy efficiency of the distinct CD8+ T cell subsets, we related 
random lymphocyte motility to mitochondrial biogenesis/ATP synthesis. 
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CD56bright Natural Killer Cells Expand and Contract Irrespective from 
CD25 Antibody-Treatment in Kidney Allograft-Recipients 
 
Introduction 
Natural killer (NK) cells are a key element of the early innate immune response.1,2  Little 
is known about possible functions of human NK cells in solid-organ transplantation.  In 
the murine system, however, compelling evidence has accumulated suggesting NK 
cells play important roles in this setting.3-5 
Phenotypically NK cells can be defined as CD3 (TCR) negative, CD56 (neural cell 
adhesion molecule) positive lymphocytes.  Approximately 90% of all circulating NK cells 
express intermediate levels of CD56 (i.e. they are CD56dim), whereas the remainder 
~10% express high levels of CD56 (CD56bright).6,7  CD56dim NK cells are efficient killer 
cells, CD56bright NK cells contain low levels of perforin and granzymes yet can be 
induced to rapidly secrete large amounts of cytokines (‘regulatory’ NK cells) 8,9.  While 
the precise relation between these phenotypically distinct subsets remains unclear it 
has been suggested that CD56dim NK cells directly derive from the CD56bright subset.10,11 
Anti-CD25 mAb are blocking the binding site for IL-2 on the α-chain of the receptor,12,13 
a principle widely used to suppress both auto- and allo-immune responses.14-16  A 
detailed understanding of how blocking the binding of IL-2 to the high-affinity IL-2 
receptor relates to this mAb’s in vivo effect is lacking. 
In patients with multiple sclerosis and active uveitis, blocking CD25 has recently been 
shown to increase the number of circulating CD56bright NK cells.17  Expansion of these 
CD56bright ‘regulatory’ NK cells has been suggested to mediate the mAb’s 
immunomodulatory effect.  No data are available on how anti-CD25 mAb-treatment 
impacts on the frequency of NK cell-subsets in kidney allograft recipients in vivo. 
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Here we took advantage of a well-characterized prospective cohort of kidney transplant-
recipients treated with anti-CD25 mAb to assess the effect of blocking CD25 with 
regards to the number and phenotype of circulating NK cells. 
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Patients and Methods 
Isolation of peripheral blood mononuclear cells 
Anticoagulated blood was drawn from 5 healthy blood donors and 16 renal transplant 
recipients before transplantation, and at week 12, 26 and 52 post-transplantation.  
Written informed consent was obtained from all study participants and the study was 
IRB approved.  Peripheral blood mononuclear cells (PBMC) were isolated using 
standard density gradient protocols (Lymphoprep, Fresenius Kabi, Oslo, Norway).   
FACScan analyses 
The following antibodies were used: CD16 (3G8), CD56 (MY31), CD3 (SK7), IL-10 
(JES3-19F1), IFN-γ (25723.11), and appropriate isotype control antibodies, all from BD 
Biosciences (San Jose, CA, USA).  For staining, cells were resuspended in PBS/1% 
bovine serum albumin (BSA, Sigma-Aldrich, Steinheim, Germany) and incubated with 
relevant antibodies for 20-40 min. at 4°C.  Data were acquired with a FACS Calibur flow 
cytometer (Becton Dickinson) gating on CD3 negative cells in the FSC/SSC lymphocyte 
gate, and analyzed using FlowJo software 8.6.3 (Tree Star, Inc., Ashland, USA). 
Intracellular cytokine staining 
After activation with PMA (25 ng/mL) and ionomycin (1 µg/mL) (both from Sigma) for 
4 h, cells were labeled with anti-CD3, anti-CD16 and anti-CD56 mAbs.  Cells were then 
fixed and permeabilized using the Cytofix/Cytoperm kit from BD BioScience according 
to the manufacturer's protocol, incubated for 40 min. with anti IFN-γ mAbs, or 
appropriate isotype control antibodies (both from BD BioScience) and washed 
extensively prior to data acquisition. 
Statistical analysis 
Results were tested for normality using the D'Agostino & Pearson omnibus normality 
test.  Student’s t-test, Mann-Whitney test and Wilcoxon’s signed rank test and 
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Fisher`s exact test were performed to assess normally and non-normally distributed 
data as appropriate, using Prism4 software (GraphPad Software, Inc. San Diego, CA, 
USA).  P values <0.05 were considered statistically significant.  Results are given as 
mean ± standard deviation (SD) or median and range, as appropriate. 
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Results and Discussion 
Immunomodulatory (‘regulatory’) effects of CD56bright NK cells have been proposed to 
mediate the effect of anti-CD25 mAb in patients with multiple sclerosis and uveitis.18,19  
Rapid production of cytokines and access to lymphnodes (via expression of lymph-
nodes-homing receptors) is thought to relate to these immunomodulatory effects of the 
CD56bright NK cell-subset,20-23 all characteristics that we could readily confirm in a series 
of set-up experiments (data not shown). 
In the circulation of 16 anti-CD25 mAb-treated kidney-transplant recipients we then 
monitored the frequency of CD56bright (and CD56dim) NK cells before transplantation, and 
at week 12, 26 and 52 post-transplantation.  In 5 healthy blood-donors tested at these 
same time-intervals circulating NK cell-subsets (CD56bright vs. CD56dim) remained stable 
(‘stable’ defined as <1.5-fold expansion/contraction relative to baseline) (data not 
shown). 
Characteristics of the transplanted study population, including induction and 
maintenance immunosuppressive regimens, are summarized in Table 1.  Overall –and 
in sharp contrast to what has been observed in patients treated with CD25-blocking 
mAb in the context of multiple sclerosis and uveitis24,25– median numbers of CD56bright 
(and CD56dim) NK cells decreased after transplantation, returning to pre-transplant 
levels at week 52 post-transplantation (Fig. 1A). 
In only a subset of patients (6/16), relevant expansion of circulating CD56bright NK cell-
numbers was observed, either early (week 12), or late (week 26 or 52) after 
administering CD25-blocking mAb (Fig. 1A, red lines, expansion defined as ≥1.5-fold 
relative to baseline). 
Expansion and contraction of circulating CD56bright and CD56dim NK cell-subsets was not 
necessarily linked (as exemplified by Patients 1-3, Figure 1B), and no association 
between total NK cell-numbers and overall lymphocyte-counts was detected (Tbl. 2).  
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Intriguingly, in the subset of patients that expanded circulating CD56bright NK cells, a 
trend towards an inverse relation with total lymphocyte counts was observed (Tbl. 2). 
Comparing ’CD56bright expanders’ and ’CD56bright non-expanders’, the glomerular 
filtration rate 12 mos post-transplantation tended to be lower in patients expanding this 
subset, but this difference did not reach statistical significance (Tbl. 1).  No similar 
association with regards to transplant-function was observed between patients 
expanding vs. not expanding the CD56dim NK cell-subset (data not shown). 
Together these data indicate that among differing patient populations in vivo blockade of 
CD25 can be associated with variable (even opposite) effects with regards to the 
circulating number of NK cell-subsets.  Whether this striking difference relates to 
specific immunological settings (e.g. auto-immunity vs. allo-immunity), or to differences 
in co-factors such as medication or organ-dysfunction (here renal insufficiency) remains 
to be determined. 
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Figure 1. NK phenotype in kidney transplant recipients treated with anti-CD25 mAb 
 
(A) NK cell-subsets were enumerated before transplantation, and at week 12, 26 and 52 post-
transplantation.  Overall median numbers of both CD56bright and CD56dim NK cell contracted after 
transplantation.  In the subset of patients that expanded CD56bright NK cell-numbers (red lines), 
no relation to induction or maintenance immunosuppressive regimens or viral and bacterial 
infectious episodes was observed (Tbl. 1). 
 
 
(B) Representative examples of the NK cell-phenotype in patients with stable vs. expanding / 
contracting CD56bright and/or CD56dim NK cells.  Note that expansion and contraction of CD56bright 
and CD56dim NK cells was not necessarily linked.
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Table 1.  Characteristics of renal transplant recipients 
Patient characteristics Expanders Non expanders p-valuea 
Patient number 6 10  
Age - median (range) 56 (40-67) 52 (32-65) 0.48 
Male gender - no. (%) 5 (86) 6 (64) 0.71 
    
Immunosuppressive regimen at tx       
Calcineurin-inhibitor based triple therapy 6 (100) 10 (100) 1 
    
Induction therapy       
Basiliximab (IL-2Ra blocker) - no. (%) 6 (100) 10 (100) 1 
    
Survival and graft function       
Patient survival, 12 mos post-tx - no. (%) 6 (100) 10 (100) 1 
Graft survival, 12 mos post-tx - no. (%) 6 (100) 10 (100) 1 
GFR, 12 mos post-tx - mL/min./1.73 m2 (mean±SD) 44.6 ± 15.2 54.2 ± 14.7  0.18 
    
Biopsy-proven rejection episodesb       
0-3 mos    
No (or borderline) rejection - no. (%) 6 (100) 10 (100) 1 
    
4-12 mos    
No (or borderline) rejection - no. (%) 6 (100) 10 (100) 1 
    
Viral and bacterial infectious-episodes       
EBV reactivation - no. (%) 0 0  
CMV reactivation - no. (%) 2 (33) 3 (30) 1 
Bacterial infections - no. (%) 3 (50) 4 (40) 1 
    
a Mann-Whitney U test for continuous variables and Fisher`s exact test for categorial variables  
bClassified according to Banff-criteria 26    
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Table 2.  Total lymphocyte counts of renal transplant recipients 
Expanders (n=6) median (range) *10^9 lymphocytes / mL  p value1 
Before Transplantation 1.2 (0.71 - 1.62)   
Week 12 0.98 (0.78 - 1.06) 0.09 
Week 26 0.89 (0.78 - 1.14) 0.06 
Week 52 1.27 (0.77 - 1.88) 0.84 
   
Non expanders (n=10) median (range) *10^9 lymphocytes / mL  p value1 
Before Transplantation 1.195 (1.07 - 3.02)   
Week 12 1.075 (0.36 - 2. 07) 0.23 
Week 26 1.24 (0.33 - 2.14) 1.00 
Week 52 1.38 (0.71 - 1.82) 0.76 
   
1 p value: total lymphocytes before transplantation compared to total lymphocytes at week 12, 26 and 52  
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Detection of Alloreactive NK cells in Mixed Lymphocyte Reactions 
using Paraformaldehyde-Silenced Target Cells 
 
Text 
Since its introduction in 1963/64,1-3 studies based on the mixed lymphocyte reaction 
(MLR) have contributed significantly to our understanding of allo-specific immunity.4  In 
response to allo-antigen exposure, reactive cells may proliferate, mature and/or secrete 
various cytokines.  To evaluate alloreactive proliferation selectively, target cell-division 
can be blocked efficiently (e.g. with mitomycin C or via irradiation).5  While proliferation 
is still used as read-out for alloreactivity, measuring the release of cytokines may be 
more sensitive to detect allo-specific lymphocyte activation, and is performed routinely.  
When investigating one-way, allo-specific induction of cytokines, irradiation is widely 
used to inhibit protein-secretion in the target cell-population. 
Using ELISpot analyses, we reassessed the effect of irradiation with the classic 
'silencing'-dose (30 Gy) on the capacity of peripheral blood mononuclear cells (PBMCs) 
to secrete IFN-γ and IL-10 after 12 h of activation (Material and Methods for details).  
PBMCs irradiated with 30 Gy, and subsequently activated with PHA at a concentration 
of 1.8 µg/ml, still secreted readily detectable amounts of IFN-γ (non-irradiated PBMCs; 
> 2500 SFC/10^6 cells, PBMCs irradiated with 30 Gy; 650 [±202] SFC/10^6 cells).  By 
contrast, irradiation of PBMCs with 75.5 Gy completely abolished secretion of IFN-γ 
(Fig. 1A, left panel).  Unlike secretion of IFN-γ, the release of IL-10 was – as observed in 
this short-time incubation assay – constitutive in nature, rather than PHA-induced.  
Importantly, this constitutive release of IL-10 was largely unaffected by irradiation with 
75.5 Gy (the dose that consistently abolished secretion of IFN-γ), and was readily 
detectable upon 12 h of incubation even after irradiation with 226.5 Gy (Fig. 1A, right 
panel).  By use of a sensitive chemiluminescence-based cytokine detection system (see 
Material and Methods for details) we expanded our assessment of irradiated PBMCs 
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(75.5 Gy) with regards to their capacity to secrete GM-CSF, IL-12, IL-1β, IL-2, TNF-α, 
and IL-6.  These experiments identified that a significant amount of GM-CSF, IL-1β,    
IL-2, TNF-α, and IL-6 are produced by PBMCs after exposure to a dose of irradiation 
that is 'silencing' the release of IFN-γ  (Fig. 1B, upper panel).  In an ideal one-way MLR 
concerned with the release of cytokines, the 'target' or 'stimulatory' cell-population 
would, with the exception of being unable to secrete cytokines, remain intact with 
regards to its biological/immunological behavior.  As evidenced here, as well as by large 
amount of literature (for review see Ref. 6-8) irradiation is far from inducing such a state 
of selective secretory anergy. 
We then tested the impact of paraformaldehyde 0.1% (10 min. exposure) on the 
secretion of cytokine by PBMCs (see Material and Methods for details).  This mild and 
short-term fixation-protocol completely abolished secretion of all cytokines tested 
(Fig. 1B, lower panel). 
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Figure 1. Effect of irradiation and formaldehyde-exposure on the release of cytokines by 
PBMCs  
 
 
 
 
 
(A) γ-irradiation reduced the frequency of IFN-γ-producing cells detectable after 12 h of activation 
with PHA (1.8 µg/ml) in a dose-dependent manner (left panel) (30 Gy: n=5, 75.5 Gy: n=15).  
Secretion of IL-10 was constitutive in nature and not further induced upon over-night activation 
with PHA (1.8 µg/ml).  Note that increasing doses of γ-irradiation slightly reduced, yet were 
unable to abolish, constitutive secretion of IL-10 (right panel) (n=3-7). 
 
 
 
(B) Using a sensitive chemiluminescence-based detection system, secretion of GM-CSF, IL-12,  
IL-1β, IL-2, TNF-α, and IL-6 by PBMCs was detected even after exposure to a dose of irradiation 
that is 'silencing' the release of IFN-γ (upper panel) (n=3).  Mild and short-term exposure of 
PBMCs to paraformaldehyde (0.1% for 10 min.) abolished both PHA-inducible as well as 
constitutive secretion of all cytokines assessed (lower panel) (n=6).  n/a=non-activated, 
PHA=activated with phytohemagglutinin. 
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Natural killer (NK) cells, a subset of lymphocytes, are a key-element of the early innate 
immune-response, and capable to rapidly produce significant amounts of various 
cytokines.9  NK cells express a complex set of receptors for HLA class I molecules (HLA-
A, -B, -C, -G, -E) that belong either to the family of killer-cell immunoglobulin-like 
receptors (KIRs), or the lectin-like receptor family.10  NK cell alloreactions seem to be 
mediated via mismatched HLA class I ligands and their receptors.  Of these, the 
dominant pattern of alloreactivity is thought to be due to two epitopes on HLA-C, 
determined by a simple amino-acid dimorphism.  Absence of any of these two HLA-C 
epitopes vis-à-vis a given NK cell is leading to a lack of inhibition of the corresponding 
KIRs expressed on this NK cell, and hence to its allo-specific activation.  
Aiming at exploiting this NK cell alloreactivity to test the usefulness of paraformaldehyde-
fixed (and hence truly silenced) target cells in MLRs, NK cells were isolated from PBMCs 
(see Material and Methods for details).  Purity of NK cell-preparations were assessed by 
flow-cytometry, and contained 96% (±2%) CD56+ CD3- cells with only 2% (±2%) 
contaminating CD3+ cells (data not shown).  First we confirmed that target cells treated 
according to the here-developed protocol retain their capacity to induce NK cell allo-
specific proliferation (Fig. 2A, representative of n=3).  Attempting next to assess NK cell 
alloreactivity in strict one-way MLRs, we then tested whether paraformaldehyde-treated  
– and hence truly silenced – target cells still were capable of triggering allo-specific 
secretion of cytokines.  Importantly (and to our knowledge for the first time), allo-specific 
IFN-γ-production was readily detected (Fig. 2B, left panel, representative of n=5).  In 
addition, our modified experimental conditions also allowed assessing the frequency of 
IL-10-secreting NK cells, which would have been hindered in MLRs using irradiated target 
cells (see Fig. 1A/B for levels of cytokines secreted by 75.5 Gy-irradiated PBMCs). 
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Figure 2. Reactivity of NK cells vis-à-vis formaldehyde-exposed target cells 
 
(A) Allo-specific proliferation of NK cells was readily detected after 5 days incubation with target 
cells silenced according to the here described fixation-protocol. 
 
 
   IFN-γ      IL-10 
 
(B) Allo-specific secretion of IFN-γ was detected exposing individual a (HLA C1/C2 haplotype) to 
target cells from individual b (HLA C2/C2 haplotype).  No reactivity was seen exposing 
individual a (HLA C1/C2 haplotype) to target cells from individual c (HLA C1/C2 haplotype).       
A tendency towards an increase in the frequency of IL-10 producing NK cells was observed 
exposing individual a (HLA C1/C2 haplotype) to target cells from individual c (HLA C1/C2 
haplotype). 
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Avoiding irradiation of target PBMCs in MLRs offers the obvious advantage of getting rid 
of a complex, target cell-derived cocktail of cytokines potentially impacting (both directly 
and possibly also indirectly) on the assay.  Continuously reevaluating the limits and 
potential pitfalls of (even long-standing) protocols is important.  In the case of the one-
way MLR, a simple modification in preparing target cells offers a means to avoiding the 
complexities introduced via their irradiation, and enhances the scope of the assay.  
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Material and Methods 
Isolation of PBMCs / NK cells 
Anticoagulated blood was drawn from healthy donors after written informed consent and 
IRB-approval.  PBMCs were isolated from buffy coats using standard density gradient 
protocols (Lymphoprep, Fresenius Kabi, Oslo, Norway).  NK cells were negatively 
selected using a human NK cell isolation kit (Miltenyi Biotecs GmbH, Bergisch-
Gladbach, Germany), according to the manufacturers protocol.  After negative selection, 
purity of cell-preparations were assessed via flow cytometry. 
FACScan analyses 
The following antibodies were used: CD16 (3G8), CD56 (MY31), CD3 (SK7), CD4 
(RPA-T4), and appropriate isotype control antibodies, all from BD Biosciences (San 
Jose, CA, USA), Ki67 (clone Ki67) (DakoCytomation, Dako Schweiz AG, Switzerland).  
Cells were resuspended in phosphate-buffered saline (PBS)/1% bovine serum albumin 
(BSA), and incubated with relevant antibodies for 30-45 min. at 4°C.  Data were 
acquired with a FACS Calibur flow cytometer (Becton Dickinson, Mountain View, CA, 
USA) and analyzed using CellQuest software (Becton Dickinson). 
ELISpot assay 
MultiScreen HTSTM IP 96 well plates (MSIPS4510, Millipore AG, Volketswil, 
Switzerland) were coated with 1:2000 diluted mAb anti-human IFN-γ (1-D1K) and anti-
human IL-10 (9D7) (both from Mabtech AB, Stockholm, Sweden).  Cells were added to 
a final volume of 130 µl/well.  After incubation, plates were washed with PBS and, prior 
to developing, incubated with PBS containing 1% FCS for 10 min.  Plates were 
incubated for 2 h with anti-human IFN-γ mAb (1:200) coupled with alkaline phosphatase 
(7-B6-1-ALP), and biotinylated anti-human IL-10 mAb (1:2000) (12G8-Biotin) (both from 
Mabtech) for 2 h at RT, washed and incubated with Streptavidin-HRP (1:2000) 
(Mabtech).  Spots were developed using HistoMark® RED phosphatase system (KPL, 
Gaithersburg, Maryland, USA) and HistoMark® True BLUE peroxidase system, and 
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counted by direct visualization with the AID CytoSpot Reader System (CSR01, AID 
GmbH, Strassberg, Germany) using the ELISpot 3.5 software (AID GmbH).  The mean 
of the negative controls plus 3 standard deviations (SD) was considered as cut-off for a 
positive result. 
Mixed lymphocyte reaction 
Irradiation of target cells: PBMCs were resuspended in PBS for irradiation (30 Gy to 
226.5 Gy, as indicated [Cs source]).  After irradiation, cells were washed twice in PBS, 
and resuspended at 3.3x107 cells/ml in R10 (RPMI 1640 containing 10% heat 
inactivated FCS, 50 U/ml penicillin and 50 µg/ml Streptomycin [all from GIBCO, 
LuBioScience GmbH, Luzern, Switzerland]). 
Paraformaldehyde-treatment of target cells: PBMCs were resuspendend in freshly 
prepared PBS 0.1% paraformaldehyde (Merck KGaA, Darmstadt, Germany), and 
incubated for 10 min. at RT.  Cells were then washed twice in PBS and quenched with 
0.1M L-lysine buffer (Sigma-Aldrich, St Louis, MO) pH 8 for 30 min. at 4°C.  Prior to use 
cells were washed 3 times in PBS and were resuspended at 1x107 cells/ml in R10. 
Cytokine-secretion assays were performed in MultiScreen HTSTM IP 96 well plates 
(Millipore AG).  Isolated NK cells (1x105 for MLRs using paraformaldehyde-treated 
target cells, 2.5x105 using irradiated target cells), and target PBMCs were added to the 
wells at a ratio of 1:5 (optimal ratio [data not shown]), and incubated in R10 overnight at 
37°C, 5% CO2.  Non-stimulated NK cells were used as negative control, NK cells 
stimulated with purified PHA (1.8 µg/ml) (Lenexa) as a positive control. 
To assess proliferation, NK cells were incubated with autologous and allogeneic 
paraformaldehyde-fixed target cells in a ratio 1:5 (ratio as optimized for the ELISpot 
assays) for 5 days at 37°C 5% CO2 (n=3).  Cells were then stained with surface 
antibodies (anti-CD3, anti-CD16, and anti-CD56) before being fixed and permeabilized 
using an intracellular staining kit according to the manufacture's protocol 
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(Cytofix/Cytoperm Kit, BD Biosciences).  After permeabilization, cells were stained with 
anti-Ki67 mAb for 30 min. at 4°C and analyzed by flow cytometry. 
Quantification of cytokines 
Relevant supernatants from target cell-cultures were transferred to MSD® 96-well 
MULTI-SPOT® plates (Meso Scale Discovery, Gaithersburg, MD, USA), and cytokines 
quantified according to the manufacturers protocol.  Plates were analyzed with the 
SECTOR Imager 6000 (MSD). 
HLA typing 
HLA-A, -B, -C typing of the responder and stimulator cells was performed by reverse 
PCR-SSOP (sequence-specific oligonucleotide probe) hybridization (LabScreen, 
OneLambda), using genomic DNA extracted from PMBCs.  Assignment to C1 and C2 
alleles was based on the presence of Asn80 and Lys80, respectively, on the α-helix of 
HLA-C antigens. 
Statistical analysis 
Mann-Whitney U tests and Student t-tests were performed for assessing normally and 
non-normally distributed data, respectively, using Prism3 software (GraphPad Software, 
Inc. San Diego, CA, USA).  P values < 0.05 were considered statistically significant.  
Results are given as mean ±SD. 
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HLA C Allotypes Differentially Support Regulatory Allo-Specific   
NK Cell-Function 
 
Introduction 
Natural killer cells (NK cells) are a key element of the early innate immune response.  
Based on their expression of CD56 (neural cell adhesion molecule) and CD16 (FcγRIII), 
NK cells can be divided into two subsets.  Approximately 90% of all circulating NK cells 
express CD56 and CD16, the remainder ~10% are CD56bright CD16dim/negative.1  Whereas 
CD56dim NK cells are efficient killer cells, CD56bright NK cells contain low levels of perforin 
and granzymes, but, when activated by cytokines in vitro, can be induced to secrete large 
amounts of inflammatory and –to some extent– anti-inflammatory cytokines.2,3 
Downregulation of HLA I molecules after viral infections or on tumor cells leads to a lack 
of inhibitory signals and hence killing of the target cell ('missing self' recognition).4-7  The 
same 'missing self' principle is thought to underlie NK cell allo-reactive killing.  The 
dominant pattern of NK cell alloreactivity is due to recognition by the NK cell of two 
HLA C allotypes, determined by an asparagine/lysine polymorphism at position 80.8-10  
Lack of recognition of these two HLA C epitopes vis-à-vis a given NK cell leads to a loss 
of inhibition of the corresponding NK cell, and hence to its allospecific activation.  In 
hematological stem cell transplantation, such 'missing self' reactions –in the sense of 
NK cell-mediated graft versus leukemia effects from HLA C mismatched donors– have 
been demonstrated to exert powerful graft-versus-leukemia effects.11,12  The role human 
allo-specific NK cells play in solid-organ transplantation remains largely unknown.13,14 
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Material and Methods  
Isolation of peripheral blood mononuclear cells and natural killer cells 
Anticoagulated blood was drawn from healthy blood donors after written informed 
consent was obtained from all study participants and IRB approval of the study.  NK 
cells were negatively selected from PBMC using NK cell isolation kits (Miltenyi Biotec 
GmbH, Bergisch-Gladbach, Germany) according to the manufacturer's protocol.  The 
purity of the NK cells was assessed by flow cytometry and was ≥98% (data not shown). 
HLA genotyping 
HLA genotyping was performed by SSO (sequence-specific oligonucleotide probe) 
hybridization (Labtype SSO, OneLambda, Montpellier, France), using genomic DNA 
extracted from PBMC. Assignment to C1 and C2 allotypes was based on the presence 
of Asn 80 and Lys 80, respectively, on the α-helix of HLA C molecules.15 
NK cell cloning and chromium release assays 
HLA C1/C2 NK cell-clones were generated by limiting dilution, using irradiated 
PBMC as feeder cells.  NK cells were plated at a concentration of 1-20 cells/100 µl, 
feeder cells were irradiated with 25 Gy and added at a concentration of 
1x106 cells/mL.  NK cells were activated with 1 µg/mL phytohaemaglutinin (PHA) 
(Remel Europe Ltd, Dartford, UK) on day 1, and 500 IU of IL-2 (Proleukin Novartis 
Pharma, Basel, Switzerland) from day 2 on.  A total of 100 NK cell-clones were 
tested for alloreactivity by (51)Cr release cytotoxicity assays at a ratio of 1:5.  Target 
cell lysis of >20% was considered significant. 
Mixed lymphocyte reaction using paraformaldehyde-silenced target cells 
Target cells were prepared as previously described.16  Briefly, PBMC were resuspended 
in freshly prepared phosphate-buffered saline (PBS) 0.1% paraformaldehyde (Merck 
KGaA, Calbiochem, Darmstadt, Germany), and incubated for 10 min. at room 
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temperature.  Cells were then quenched with 0.1M L-lysine buffer (Sigma-Aldrich, St 
Louis, MO, USA).  MHC I expression was not influenced by this procedure (data not 
shown).  Prior to use, cells were resuspended at 1x107 cells/mL in R10 (RPMI 1640 
containing 10% heat-inactivated FCS, 50 U/mL penicillin and 50 µg/mL streptomycin [all 
from GIBCO, LuBioScience GmbH, Luzern, Switzerland]).  When mixed lymphocyte 
reactions (MLRs) were followed by qPCR experiments, target cells were depleted from 
CD56-expressing cells by use of CD56 MACS beads (>98% depletion-efficiency, data 
not shown) (Miltenyi Biotec). 
MLRs were performed in MultiScreen HTSTM IP 96 well plates (MSIPS4510, Millipore 
AG, Volketswil, Switzerland) or in Microtest tissue culture 96 well plates (Becton 
Dickinson, Mountain View, CA, USA). Effector cells (1x105 isolated NK cells) were 
incubated with PBMC as target cells at a ratio of 1:5 (=optimal ratio [data not shown]).  
All MLRs were performed overnight in R10 at 37°C, 5% CO2.  As negative control, fixed 
target cells were used.  NK cells stimulated with phorbol myristate acetate (PMA) 
(20 ng/mL) and ionomycin (2 µM) (both from Merck KGaA, Calbiochem) served as 
positive control. 
Cell-densities of all experimental settings ('autologous–low density' [1x106 NK cells/mL]; 
'autologous–high density', 'allo-C1/C1', 'allo-C1/C2' and 'allo-C2/C2' [=all 'high density', 
1x106 NK cells plus 5x106 autologous or allogeneic cells/mL; 100 µl plated in 6.35 mm 
diameter flat bottom plates]) were documented using an Olympus IX50 Inverted Phase 
Contrast microscope (Olympus Schweiz AG, Volketswil, Switzerland). 
ELISpot assay 
MultiScreen HTSTM IP 96 well plates (Millipore AG) were coated with 1:2000 diluted 
mAb anti-human IFN-γ (1-D1K) and anti-human IL-10 (9D7) (both from Mabtech AB, 
Stockholm, Sweden).  Cells were added to a final volume of 130 µl/well.  After 
incubation, plates were incubated for 2 h with anti-human IFN-γ mAb (1:200) coupled 
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with alkaline phosphatase (7-B6-1-ALP), and biotinylated anti-human IL-10 mAb 
(1:2000) (12G8-Biotin) (both from Mabtech) for 1.5 h at room temperature, washed 
and incubated with Streptavidin-HRP (1:2000) (Mabtech).  Spots were developed 
using HistoMark® RED phosphatase system and HistoMark® True BLUE peroxidase 
system (both from KPL, Gaithersburg, Maryland, USA), and counted by direct 
visualization with the AID CytoSpot Reader System (CSR01, Autoimmun Diagnostika 
(AID) GmbH, Strassberg, Germany) using the ELISpot 3.5 software (AID GmbH). 
Quantitative PCR (qPCR) 
Total RNA was extracted from NK cells that were either isolated directly from PBMC, or 
negatively selected after MLRs (NK cell purity was always >98%, data not shown), 
using the RNeasy Mini kit (QIAGEN GmbH, Hilden, Germany).  Total RNA was used for 
reverse transcription (Promega, Madison, WI, USA). For qPCR, 2-4 µl of cDNA were 
used on an ABI 7900 instrument, using TaqMan chemistry (Applied Biosystems, Foster 
City, CA, USA).  Values are given as copies over copies of β2-microglobulin.  Primers 
and probes used in this study are listed in Table 1. 
Table 1. Primers and probes 
 
Assay Primers Probe 
IL-10 F: GCCTTGTCTGAGATGATCCAGTT ATGCCCCAAGCTGAGAACCAAGACC 
   R: TCACATGCGCCTTGATGTCT  
TGF-β F: CGAGAAGCGGTACCTGAAC CAGCACGTGGAGCTGTACCAGAAATACAGC 
 R: TGAGGTATCGCCAGGAATTGT  
Statistical analysis 
Results were tested for normality using the D'Agostino & Pearson omnibus normality 
test.  Mann-Whitney U test and Wilcoxon’s signed rank test were performed as 
appropriate, using Prism4 software (GraphPad Software, Inc. San Diego, CA, USA).     
P values <0.05 were considered statistically significant.  Results are given as mean ± 
standard deviation (SD) or median and range, as appropriate. 
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Results 
Allo-specific killing and secretion of IFN-γ and IL-10 by NK cells 
Ex vivo expanded and activated NK cell-clones readily kill allo-target cells (Ref. 17 and 
Fig. 1).  To begin to understand how allo-specific NK cell-mediated killing relates to their 
secretion of cytokines, we applied a recently developed method to completely inhibit the 
cytokine-secretion capacity of target cells used in MLRs.18 
 
 
 
 
 
 
 
 
Figure 1. Allo-specific killing by NK cells 
NK cells expressing HLA C1 and C2 were cloned and tested for alloreactivity in chromium 
release assays.  Cytotoxicity was defined as ≥20% killing of target cells.  Cytotoxic clones were 
exclusively detected when target cells lacked expression of HLA C1 or HLA C2. 
 
Surprisingly, using this system to assess NK cells directly ex vivo, a population of NK 
cells secreting the regulatory cytokine IL-10 was identified.  This secretion of IL-10 was 
not constitutive, since NK cells plated at a concentration not allowing for cell-cell 
interaction (‘low-density’ plating, Fig. 2A, left panel) did not secrete IL-10, or did so only 
at very low levels.  However, when plating NK cells at a density promoting extensive 
cell-cell interactions (‘high-density’ plating, Fig. 2A, right panel), a population of NK cells 
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secreting IL-10 was consistently induced (Fig. 2B, left panel).  The median frequency of 
this population increased when increasing the target to effector (i.e. NK) cell-ratio –with 
a plateau being reached at a target to effector cell-ratio between 5:1 and 10:1– and was 
induced irrespective of whether PBMC or isolated NK cells were used as target cells 
(data not shown).  Variability of the population-size of IL-10 secreting NK cells was not 
related to their own HLA C genotype, nor was the HLA C genotype of NK cells related to 
the frequency of IL-10 secretion in allogeneic reactions (data not shown).  Interestingly 
however, frequencies of IL-10 secreting NK cells were found to differ depending on the 
HLA C genotype of the allo-target cell population.  Exposure to target cells with a C1/C2 
genotype even increased the median frequency of IL-10 secreting NK cells as 
compared to the ‘autologous-high density’ condition (p=0.03), and was higher than after 
exposure to allo-target cells with a C1/C1 or a C2/C2 genotype (Fig. 2B, right panel).  
The relation between the frequency of IL-10 secreting NK cells and the HLA C genotype 
of the allo-target cell population became even more evident when directly comparing 
reactions of NK cells against both allo-target cells with a C1/C2 genotype and allo-target 
cells with a C1/C1 genotype, or –alternatively– allo-target cells with a C1/C2 genotype 
and allo-target cells with a C2/C2 genotype.  In 13/14 (93%) experiments the frequency 
of NK cells secreting IL-10 was higher when reacting against allo-target cells with a 
C1/C2 genotype than when reacting against allo-target cells with a C1/C1 genotype 
(p=0.0005), and in 4/5 (80%) reactions the frequency of NK cells secreting IL-10 was 
higher when reacting with allo-target cells with a C1/C2 genotype as compared to 
reactions against allo-target cells with a C2/C2 genotype. 
Dual-color ELISpot analyses allowed discriminating the source of IL-10 vs. IFN-γ at the 
single-cell level and indicated that NK cells never simultaneously secreted both IL-10 
and IFN-γ (Fig. 2C).  Flow-cytometric experiments gating on CD3- CD56+ lymphocytes 
and staining for intracellular IL-10 confirmed these ELISpot based observations (data 
not shown). 
47  
Together these experiments indicated that a distinct population of unprimed NK cells 
could be induced to secrete IL-10 directly ex vivo.  The relative frequencies of IL-10 
secreting NK cells related to the HLA C allotype of allo-target cells.  
 
Figure 2. Killing-activity and secretion of IFN-γ  and IL-10 by NK cells interacting with 
autologous and allogeneic target cells 
 
 
 
 
 
 
 
 
 
 
(A) Throughout the manuscript secretion of cytokines by NK cells was tested either under 
experimental conditions allowing only for limited cell-cell contacts (termed ‘autologous–low 
density’) (left panel=representative), or conditions promoting extensive cell-cell contacts (termed 
‘autologous–high density’, ‘allo C1/C2’, ‘allo C1/C1’ or ‘allo C2/C2’) (right panel=representative). 
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(B) The impact of NK cell–target cell interactions on NK cell-derived secretion of IL-10 was 
assessed using ELISpot assays.  Under ‘autologous–low density’ conditions, NK cells secreted 
little, if any, IL-10.  By contrast, ‘autologous–high density’ conditions consistently induced a 
population of NK cells to secrete IL-10.  Under allo-conditions, NK cell–target cell interactions 
also induced an IL-10 secreting NK cell-population.  Grouping allo-target cells according to their 
HLA C genotype, cells expressing both HLA C1 and C2 epitopes best supported –or even 
enhanced– secretion of IL-10 by NK cells.  Horizontal lines indicate median values.  ***P<0.0001 
 
 
 
 
 
 
 
 
 
 
(C) In dual-color ELISpot assays, secretion of IL-10 (blue spots) and IFN-γ (red spots) was 
assessed at the single-cell level.  Only single-positive NK cells were detected. 
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Secretion of TGF-β by NK cells after mixed lymphocyte reactions 
TGF-β is a pleiotropic cytokine with immunoregulatory properties.19  Using a sandwich 
ELISA-system we measured the concentration of TGF-β in the supernatant of NK 
cells plated at low density ('autologous–low density'), exposed to silenced autologous 
cells ('autologous–high density'), as well as silenced 'allo-C1/C2', 'allo-C1/C1', and 
'allo-C2/C2' target cells.  In the supernatant of NK cells plated at a concentration 
preventing extensive cell-cell contact ('autologous–low density'), concentrations of 
TGF-β were at –or below– background levels of the assay.  By contrast, autologous 
cellular interactions ('autologous–high density') induced NK cells to release 
considerable amounts of TGF-β (Fig. 3, left panel).  In line with the data obtained for 
secretion of  IL-10, interaction with allo-target cells differentially supported secretion of 
TGF-β by NK cells.  Whereas similar levels were detected after exposure of NK cells 
to autologous cells and 'allo-C1/C2' target cells, less TGF-β was released after 
exposure of NK cells to 'allo-C1/C1' target cells and 'allo-C2/C2' target cells (Fig. 3, 
right panel). 
Thus, autologous cell-cell interactions actively induced NK cells to secrete TGF-β.  
Under allo-conditions this secretion was only supported by target cells expressing both 
HLA C1 and C2 epitopes.  
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Figure 3. Secretion of TGF-β  by NK cells interacting with autologous and allogeneic target 
cells 
The concentration of TGF-β secreted by NK cells was measured by ELISA after overnight MLRs.  
Significantly more TGF-β was detected in the supernatant from NK cells plated at ‘autologous-
high density’ conditions as compared to NK cells plated at ‘autologous–low density’ conditions.  
‘Allo C1/C2’ target cells best supported this cell-contact mediated secretion of TGF-β.  Horizontal 
lines indicate median values.  ***P<0.0001 
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mRNA levels of IL-10 and TGF-β in NK cells after mixed lymphocyte reactions 
Using standard qPCR technology we also quantified NK cell-derived mRNA for IL-10 
and TGF-β after MLRs.  Analogous to the above experiments that assessed IL-10 and 
TGF-β at the protein level, mRNA was quantified in NK cells that were plated at 
concentrations not supporting extensive cell-cell interactions ('autologous–low density', 
n=3), and compared to levels in NK cells plated so as to allow for extensive cell-cell 
contact (either 'autologous–high density' or 'allo C1/C2', 'allo C1/C1', and 'allo C2/C2'; 
n=3 for each MLR-constellation). 
In NK cells plated at low density, no message for IL-10 and only low levels of message 
for TGF-β was detected.  Plating NK cells under 'autologous–high density' conditions 
induced detectable amounts of IL-10 mRNA, whereas levels for TGF-β mRNA remained 
detectable at low levels.  Importantly, after exposure of NK cells to 'allo C1/C2' target 
cells –i.e. the MLR-constellation best supporting or even enhancing production of IL-10 
and TGF-β at the protein level– message for both IL-10 and TGF-β was best induced 
(Fig. 4). 
These experiments supported a model in which –also at the mRNA level– autologous 
cell-cell contacts, and interactions with allo-target cells co-expressing C1 and C2 
epitopes, induced/supported production by NK cells of the regulatory cytokine IL-10, 
and revealed that mRNA for TGF-β was best induced after exposure of NK cells to allo-
target cells co-expressing C1 and C2 epitopes. 
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Figure 4. mRNA-levels of TGF-β  and IL-10 in NK cells interacting with autologous and 
allogeneic target cells 
IL-10 and TGF-β mRNA levels from NK cells were quantified after overnight MLRs.  In non-
stimulated NK cells plated at ‘autologous–low density’ conditions, no message for IL-10 and low 
amounts of message for TGF-β were detected.  Plating NK cells at ‘autologous–high density’ 
conditions induced mRNA for IL-10, mRNA levels for TGF-β remained unchanged.  ‘Allo C1/C2’ 
target cells further induced IL-10 mRNA and also most strongly induced TGF-β mRNA.  Results 
are given as copies over copies of β2-microglobulin.  Data are presented as mean ± SD. 
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Discussion 
The key observation of the current study was that, in absence of activating cytokines, 
'constitutive' cell–cell interactions induce –in a subset of NK cells– an active regulatory 
response.  Exposing NK cells to allo-target cells we found that specific allogeneic cell-
cell interactions support –or even enhance– 'constitutive' cell-contact dependent 
cytokine secretion (Fig. 2B).  This regulatory NK cell activity was operational directly ex 
vivo (i.e. in unprimed cells), and confined to a population distinct from IFN-γ secreting 
NK cells (Fig. 2C).20 
Pro-inflammatory and cytotoxic NK cell-function has been implicated in promoting 
allograft injury.21  Somewhat unexpectedly therefore, more recent murine data indicated 
that NK cells may also play important roles inducing certain forms of allograft 
tolerance.22  Whether NK cells impact allo-immunity in the setting of human solid organ 
transplantation remains largely unknown, and a detailed understanding of the reactivity 
of unprimed human NK cells vis-a-vis allo-target cells is lacking.  Our preliminary 
observation of a dominant impact of the recipient’s HLA C allotype on the pattern of 
cytokines induced in unprimed allo-NK cells might thus stimulate –and direct– research 
aiming at elucidating the molecular basis of this phenomenon in humans.  A provocative 
hypothesis could state that certain allo-constellations efficiently induce regulatory NK 
cells, hence providing T cells a non-inflammatory –perhaps tolerogenic– environment.  
From a more clinical point-of-view our data lend support to current efforts aiming at 
reassessing the role of HLA C in kidney allograft survival/function. 
In summary, our data identify a distinct subset of NK cells that –upon cell-cell 
interaction– are activated, rather than silenced, and secrete regulatory cytokines.  This 
novel type of NK cell reactivity may have important implications with respect to various 
aspects of NK cell-biology –and particularly NK cell allo-reactivity– in vivo. 
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A 'High-Mobility Low-Cost' Phenotype Defines Human Effector-Memory 
CD8+ T cells  
 
Introduction 
Phenotypic and immune-functional analyses have defined differences in the nature of 
CD8+ T cell populations, differing homing being one of the key distinctions among 
subsets.  Naïve and central-memory CD8+ T cells express the lymphnode homing 
receptors CCR7 and CD62L, and screen lymphoid tissue for cognate antigen.  Effector-
memory CD8+ T cells, by contrast, lack expression of CCR7 and CD62L and primarily 
home into non-lymphoid tissues.1-5  Screening for cognate antigen via random 
lymphocyte motility (‘random-walk’ activity) –an obviously energy consuming biological 
feature– has been shown to be characteristic of both, lymphoid as well as non-lymphoid 
homing CD8+ T cells.6-11  Mimicking intravascular and extravascular conditions in vitro, 
we sought here to (i) characterize random lymphocyte motility among lymphoid and 
non-lymphoid homing CD8+ T cells, and (ii) relate random lymphocyte motility and 
mitochondrial biogenesis/ATP synthesis. 
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Material and Methods 
Isolation of peripheral blood mononuclear cells and T-cells 
Anticoagulated blood was drawn from healthy donors after written informed consent.  
Peripheral blood mononuclear cells (PBMC) were isolated using standard density 
gradient protocols (LymphoprepTM, Fresenius Kabi, Oslo, Norway).  CD4+ and CD8+  
T cells were positively selected using MACS beads (Miltenyi Biotec GmbH, Bergisch-
Gladbach, Germany).  Purity of CD4+  and CD8+ Tcells, as assessed by flow 
cytometry, was always >95% (data not shown). 
Cell culture 
Human umbilical vein endothelial cells (HUVECs) were cultured in 24 or 48 well cell 
culture plates BD BioScience (San Jose, CA, USA) or on 5 µm pore size polycarbonate 
transwell inserts (Costar®, Corning Incorporated, Corning, NY, USA) in endothelial cell 
medium (EGM® - 2MV, Lonza, Basel, Switzerland) supplemented with 5% fetal calf 
serum (GIBCOTM, Luzern, Switzerland).  The medium was changed daily and cells used 
when a confluence of ~90% was reached. 
FACScan analysis  
The following antibodies were used: CCR7 (FAB197F / FAB197P) and appropriate 
isotype control antibodies from R&D systems (R&D systems Europe, United Kingdom), 
CD3 (SK7), CD4 (RPA-T4), CD8 (RPA-T8 / SK1), CD27 (M-T271), CD28 (CD28.2), 
CD44 (G44-26), CD45RA (HI100), CD62L (Dreg 56), CD69 (L78) and appropriate 
isotype control antibodies from BD Biosciences.  For staining, cells were resuspended 
in phosphate buffered saline / 1% bovine serum albumin (Sigma-Aldrich, Steinheim, 
Germany) and incubated with relevant antibodies for 20 min. at 4°C.  After extensive 
washing, data were acquired with a FACS Calibur flow cytometer (Becton Dickinson, 
Mountain View, CA, USA) and analyzed using CellQuest (Becton Dickinson) or FlowJo 
8.6.3. software (Tree Star, Inc., Ashland, OR, USA). 
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FACS sorting 
CD8+ T cell subsets (as indicated) were sorted using the BD FACSVantage SE System 
(Becton Dickinson).  Purity of CD8+ T cell subsets was assessed by post-sort flow 
cytometry and always was >98% (data not shown). 
Migration assay 
Bulk lymphocytes or sorted CD8+ T cell subsets were resuspended at 6x10^5 cells/mL 
in RPMI 1640 containing 10% fetal calf serum, 50 U/mL penicillin and 50 µg/mL 
Streptomycin (all from GIBCOTM, Luzern, Switzerland) (R10) and loaded in duplicates 
into uncoated, fibronectin coated (10 µg/mL) (Human Plasma Fibronectin, Temecula, 
CA, USA) or HUVEC coated 5 µm pore size polycarbonate transwell inserts (Costar®, 
Corning, NY, USA).  1 mL R10 or EGM® - 2MV for HUVECs, respectively, was added to 
the lower well.  After 16 h of incubation at 37°C, cells from both compartments were 
stained with the appropriate antibodies. 
ELISpot 
After transwell migration assays, CD8+ T cells from the upper and lower compartments 
were tested separately for EBV-specific IFN-γ production using ELISpot assays.  Briefly, 
MultiScreen HTSTM IP 96 well plates (Millipore AG, Volketswil, Switzerland) were coated 
over night with 1:2000 diluted mAb anti-human IFN-γ (1-D1K) (Mabtech AB, Stockholm, 
Sweden).  Isolated migrating and non-migrating CD8+ T cells were enumerated, and 
autologous CD8+ T cell depleted PBMC were added back to provide antigen presenting 
cells (APC) at a ratio of 1:5.  APC were loaded with EBV-infected –and as a control EBV 
naïve– B cell extract at a concentration of 20 µg/mL (Virusys corporation, Randallstown, 
MD, USA).  After over night incubation, plates were washed with PBS and, prior to 
developing, incubated with PBS containing 1% FCS for 10 min.  Plates were incubated 
for 2 h with anti-human IFN-γ mAb (1:200) coupled with alkaline phosphatase (7-B6-1-
ALP) (Mabtech) for 1.5 hours at room temperature.  After washing, spots were 
developed using HistoMark® RED phosphatase system (KPL, Gaithersburg, Maryland, 
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USA), and counted by direct visualization with the AID CytoSpot Reader System 
(CSR01, Autoimmun Diagnostika (AID) GmbH, Strassberg, Germany) using the 
ELISpot 3.5 software (AID GmbH). 
Time-lapse microscopy 
CCR7- CD8+ and CCR7+ CD8+ T cells were FACS sorted and resuspended in R10 
and plated in uncoated 24 or 48 well cell-culture dishes (Costar®), coated with 
fibronectin (10 µg/mL), or on HUVEC coated plates.  After an incubation period of 
1 hour, pictures were taken every minute using an Olympus IX 81 motorized inverted 
microscope (Olympus Schweiz AG, Volketswil, Switzerland).  Data were analyzed using 
the cell^P and cell^R software (professional imaging software, Olympus) and ImageJ 
software (Image Processing and Analysis, http://rsbweb.nih.gov/ij). 
ATP quantification 
FACS sorted CD8+ T cell subsets were resuspended at 1x10^6 cells/mL in purified 
water, transferred to cryotubes (Nunc A/S, Roskilde, Denmark) and snap frozen in liquid 
nitrogen.  After thawing, cells were incubated for 10 min. in boiling water and 
centrifuged for 5 min. at 20,000xg.  The supernatant was kept on ice until ATP 
measurements were performed according to the manufacturer’s protocol (FL-AA, 
Sigma-Aldrich, Steinheim, Germany). 
Gene expression analysis 
Total RNA was isolated from FACS sorted CCR7- and CCR7+ CD8+ T cells using 
TRIzol® Reagent according to the manufacturer's protocol (InvitrogenTM, Basel, 
Switzerland).  After DNA digestion, 1 µg RNA was reverse transcribed.  2 µl of a 1:3.5 
cDNA dilution were used to perform the qPCR reaction in a Stratagene cycler 
(Stratagene, La Jolla, CA) using SYBR Green master mix (Sigma).  Gene expression 
levels are given as relative gene expression compared to the housekeeping gene TBP 
(TATA-Box-binding protein).  Primers are listed in Table 1. 
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Table 1. Primers  
Assay Primers1   
hPGC-1beta (NM_133263) R: AGGTGGCCGAGTCAAAGTC  
 L: CAACTATCTCGCTGACACGC  
hERRalpha (NM_004451) R: CGCTTGGTGATCTCACACTC 
 L: GCTACCACTATGGTGTGGCA 
hAtp5o (NM_001697) R: CGGATCAGTCTTAGCCTCCA 
 L: GCACAGTGACCTCTGCATCT 
hCycs (NM_018947) R: AGATTTGGCCCAGTCTTGTG 
 L: TTGTGCCAGCGACTAAAAAG 
hUCP2 (NM_003355) R: CTGATTTCCTGCTACGTCCC 
 L: CCGTGAGACCTTACAAAGCC 
hUCP3 (NM_003356) R: ACATCACCACGTTCCAGGAT 
 L: CCTCCAGGCCAGTACTTCAG 
   
1 R: Right primer sequence, L: Left primer sequence   
 
Calorimetry 
Bulk lymphocytes and FACS sorted CCR7- and CCR7+ CD8+ T cells were 
resuspended at 1.2x10^6 or 2.4x10^6 cells/mL in R10.  After a calibration period of 24 
hours, heat production of bulk and sorted lymphocytes was recorded every minute 
during 12 hours using an isothermal calorimeter (Thermal Activity Monitor 3102 TAM III, 
TA Instruments, New Castle, DE; USA). 
Statistical analysis 
Results were tested for normality using D’Agostino&Pearson omnibus normality test.  
Student’s t-tests, Mann-Whitney U-tests and Wilcoxon’s signed rank-tests were 
performed using Prism4 software (GraphPad Software, Inc. San Diego, CA, USA).      
P-values <0.05 were considered statistically significant.  Results are given as 
mean±standard deviation (SD), or median and range, as appropriate. 
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Results and Discussion 
Random cellular movement of CD8+ T cells 
Distinct anatomical compartments are screened for cognate antigen by specialized 
subsets of T cells.1-5  ‘Antigen screening efficiency’ of T cells –both in lymphoid and 
non-lymphoid organs– is thought to be increased by random cellular movement 
(‘random-walk’).6,7,10,12-15  Aiming at assigning random cellular movement-activity to 
distinct cell-populations we first compared the phenotype of CD8+ T cells ex vivo with 
that of CD8+ T cells that –in absence of a chemotactic gradient– migrated across 5 µM 
pore-inserts coated with either fibronectin (Fig. 1A, upper panel) or human umbilical 
vein endothelial cells (HUVECs) (Fig. 1A, lower panel).  Irrespective of whether  
CD8+ T cells were interacting with fibronectin or with HUVECs, the phenotype of 
transmigrating CD8+ T cells became skewed towards cells lacking expression of the 
lymphnode homing receptors CCR7 and CD62L (Fig. 1A and Tbl. 2).   
CD8+ T cells were also stained for expression of the maturation-marker CD45RA, the 
cell-surface glycoprotein CD44 (involved in lymphocyte homing), and the activation-
marker CD69.4,16-20  Neither of these molecules was differentially expressed on non-
migrating vs. migrating CD8+ T cells (Fig. 1A).  We also used CD27 and CD28, two 
phenotypic markers of CD8+ T cell differentiation,1 to characterize cells accumulating in 
migration assays.  As for expression of CCR7 and CD62L, also according to the 
expression of CD27 and CD28 accumulation of cells with an effector-memory 
phenotype (CD27-CD28- ; ‘late differentiated’ cells) was observed (data not shown).   
We then quantified migration of sorted CCR7- and CCR7+ CD8+ T cells, by relating the 
starting number of cells to the number of cells that had migrated after 16 h of incubation.  
Indicating their higher intrinsic random movement-activity, the percentage of migrating 
cells was almost 3-fold higher among sorted CCR7- CD8+ T cells (median % of cells 
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migrating after 16h: CCR7-  27.7% [range 23.7-49.0%], n=5, CCR7+  10.1% [range 1.3-
14.4%], n=6, p=0.004).   
Lastly, we compared the size (forward scatter histogram) of migrating vs. non-migrating 
cells, thus testing –and dismissing– the hypothesis that accumulation of CD8+ T cells 
with an effector-memory phenotype merely reflected selection for smaller cells (data not 
shown). 
In parallel, migration experiments were performed using isolated CD4+ T cells.  
Increased migration of CD4+ T cells with an effector-memory phenotype, analogous to 
CD8+ T cells, was observed, and –also analogous to CD8+ T cells– no difference in the 
expression of CD45RA, CD44 or CD69 was seen (data not shown). 
In order to monitor random migration at the antigen-specific level we then compared the 
frequency of EBV-specific IFN-γ producing CD8+ T cells among non-migrating and 
migrating populations.  EBV-specific CD8+ T cells were readily detected both among 
non-migrating and migrating cells, and –on each occasion– accumulation of effector-
memory cells among the migrating cells (as shown in Fig. 1A) was reflected by an 
increase in the frequency of cells releasing the effector-cytokine IFN-γ (Fig. 1B). 
We next aimed at visualizing random migration of CD8+ T cells on fibronectin –
mimicking the extra-vascular/interstitial milieu– and on HUVECs.  Both on fibronectin 
and on HUVECs –at any given time-point– (i) crawling and (ii) non-crawling  
CD8+ T cells could be readily discerned (crawling defined here as flattening of the cell-
stoma with extension of pseudopodia; see insert in Fig. 1D).  The average speed of 
crawling cells (CCR7- and CCR7+) was similar on fibronectin and on HUVECs, whereas 
non-crawling cells (CCR7- and CCR7+) moved slightly more rapid on fibronectin –
possibly reflecting a moving-restrain imposed by the bold relief of HUVECs (Fig. 1C, 
upper panels).  Intriguingly, comparing the percentage of crawling vs. non-crawling 
CD8+ T cells on fibronectin vs. HUVECs, a striking difference was observed between 
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cells expressing vs. not expressing the lymphnode homing chemokine-receptor CCR7: 
While for each recorded time-point on fibronectin ~10% of all CCR7- CD8+ T cells 
exhibited a crawling phenotype, the frequency of CCR7+ CD8+ T cells crawling on 
fibronectin was always <2%.  By contrast, on HUVECs the percentage of crawling cells 
was higher among CCR7+ CD8+ T cells, yet it always remained <5% for both subsets 
(Fig. 1C, lower panels).  Representative live-microscopy images of CCR7- and CCR7+ 
CD8+ T cells on fibronectin and HUVECs are shown in Figure 1D, time-lapse movies 
are available at http://bloodjournal.hematologylibrary.org First edition, Supplemental 
Videos. 
Together these experiments identified robust differences between phenotypically 
distinct subsets of CD8+ T cells with regards to their random movement activity, and the 
frequency-distribution of crawling cells.  These differences may imply that stochastic 
detection of cognate antigen in the extravascular milieu at a given rate requires higher 
crawling-activity in structurally more variable non-lymphoid tissues than within 
anatomically highly defined secondary lymphnodes.  
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Figure 1. Phenotypic and functional characteristics of randomly moving of  
CD8+ T cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) In transwell migration experiments, migration of CD8+ T cells through fibronectin coated       
5 µM pore membranes (upper panel) and through HUVECs grown on 5 µM pore membranes 
(lower panel) was assessed in absence of a chemotactic gradient.  Ex vivo expression of CCR7 
and CD45RA, CD44 and CD62L, and the activation marker CD69 was compared to expression 
on migrating cells (16 hours migration).  Migrating CD8+ T cells were skewed towards a CCR7- 
and CD62L- phenotype. 
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(B) As assessed in transwell migration experiments, the frequency of EBV-specific CD8+ T cells 
producing IFN-γ was higher amid migrating than non-migrating cells.  *P<0.05 
(C) Using time-lapse microscopy, the movement-pattern of sorted CCR7- and CCR7+ CD8+      
T cells on fibronectin-coated cell culture plates and on HUVECs was visualized. The velocity of 
crawling and non-crawling cells was analyzed assessing 1 min.-spaced pictures.  The average 
speed of crawling cells was similar among subsets on both fibronectin and HUVECs, whereas 
non-crawling cells moved slightly more rapid on fibronectin (upper panel).  Crawling and non-
non migrated migrated
0
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crawling cells were enumerated on 5 min.-spaced pictures throughout a 1 hour observation 
period, and the mean percentage of crawling cells compared among CCR7- and CCR7+ CD8+ 
Tcells.  Crawling was a prominent feature of CCR7- CD8+ T cells on fibronectin (~10% of all 
cells).  On HUVECs the frequency of crawling CD8+T-cells was higher among the CCR7+ 
subset, but always remained <5% (lower panel).  ***P<0.001 
 
 
 
(D) On representative time-lapse video-pictures crawling CD8+ T cells on fibronectin and 
HUVECs are marked with a circle.  The insert shows the typical features of a crawling cell at 
higher magnification.  — = 0.1 mm 
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Table 2. Phenotype of transmigrating CD8+ T cells 
Migration through Fibronectin Ex vivo [median (range)] Migrated [median (range)] p-value 
CCR7- CD8+ T cells, n=9 37.9% (29.5-63.5) 86.4% (75.7-93.0) 0.0007 
CCR7+ CD8+ T cells, n=9 62.1% (36.5-73.2) 13.5% (7.0-24.3) 0.0007 
CD62L- CD8+ T cells, n=13 38.1% (26.7-49.7) 67.2% (48.1-74.3) 0.0002 
CD62L+ CD8+ T cells, n=13 64.1% (23.8-66.4) 23.6% (11.7-43.6) 0.0002 
    
Migration through HUVECs Ex vivo [median (range)] Migrated [median (range)] p-value 
CCR7- CD8+ T cells, n=5 30.5 % (24.19-46.5) 51.1% (42.6-87.3) 0.04 
CCR7+ CD8+ T cells, n=5 69.5% (53.5-85.9) 48.9% (12.7-57.4) 0.04 
CD62L- CD8+ T cells, n=5 32.3% ( 20.1-34.4) 43.2% (28.0-73.8) 0.03 
CD62L+ CD8+ T cells, n=5 70.2% (57.9-73.0) 46.9% (23.6-65.4) 0.03 
69  
ATP content and energy-efficiency of CCR7- versus CCR7+ CD8+ T cells 
Cellular locomotion relies on transient interactions of motor proteins with microtubules 
or actin filaments, which then activates the binding and hydrolysis of ATP.21  Using a 
robust luciferin-based assay, ATP contents were found to be consistently lower in 
CCR7- as compared to CCR7+ CD8+ T cells (CCR7- CD8+ T cells: median ATP 
content 299±62 nmol/10^6 cells, CCR7+ CD8+ T cells: median ATP content 378±62 
nmol/10^6cells, n=10, p=0.025) (Fig. 2A, left panel).  Intriguingly however, lower ATP 
contents did not simply reflect increased ATP consumption by crawling cells, since 
messenger RNA of PGC-1β (a strong activator of mitochondrial biogenesis/ATP 
synthesis), ERRα (an important partner of PGC-1), Cytochrome C (Cycs) und 
ATP Synthase (Atp5o) were all expressed at a higher level in the CCR7+ CD8+ T cell 
subset as well (Fig. 2A, right panels).22  CCR7- CD8+ T cells thus seem indeed able to 
maintain a higher crawling frequency despite lower overall ATP generation. 
To further investigate the energy-efficiency of CCR7- CD8+ T cells we next compared 
the heat-flow of sorted CCR7- and CCR7+ CD8+ T cells using microcalorimetry 
assays.23  In line with a postulated higher energy-efficiency, CCR7- CD8+ T cells 
produced a median of only 68 nW/10^6 cells (range 0-530 nW) (n=8), whereas CCR7+ 
CD8+ T cells produced a median of 390 nW/10^6 cells (range 2-1050 nW) (n=8) 
(Fig. 2B, left panel).  Surprisingly, at least part of the higher energy-efficiency of CCR7-
CD8+ T cells might be brought about via upregulation of uncoupling proteins of the 
oxidative chain (UCP-2 und UCP-3) in the CCR7+ CD8+ T cell subset (Fig. 2B, right 
panels). 
 
70 
 
Figure 2. ATP content and energy-efficiency of CCR7- versus CCR7+ CD8+ T cells  
 
(A) ATP contents of sorted CCR7- and CCR7+ CD8+ T cells were measured in a luminescence 
based assay (left panel); mRNA levels of PGC-1β, ERRα, Cytochrome C (Cycs) und 
ATP Synthase (Atp5o) were quantified using RT-PCR technology (right panels).  CCR7- CD8+   
T cells contained less ATP and expressed less mRNA for PGC-1β, ERRα, Cycs und Atp5o than 
their CCR7+ counterparts.  *P<0.05 
 
 
(B) In calorimetric analyses heat production of sorted CCR7- and CCR7+ CD8+ T cells was 
quantified.  After a calibration period of 24 hours heat production was quantified every minute for 
12 hours.  The insert shows the heat flow diagram of a representative experiment (left panel).  
mRNA levels of the uncoupling proteins 2 and 3 of the respiratory chain (UCP-2 and UCP-3) 
were quantified by RT-PCR (right panels).  CCR7- CD8+ T cells contained significantly less 
mRNA for both UCP-2 and UCP-3 than their CCR7+ counterparts.  *P<0.05 
 
As any biologically costly system, immunity has evolved to minimize energy expenditure 
in performing its task,24,25 and screening for cognate antigen within lymphoid and non-
lymphoid/peripheral tissues is bound to comply with this principle.  Our data regarding 
non-lymphoid homing CD8+ T cells recognizably comply with that principle; regulated 
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uncoupling of the respiratory chain via upregulation of uncoupling proteins, on the other 
hand, seems counterintuitive and suggests as yet unrecognized properties of 
lymphnode homing CD8+ T cells. 
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Future perspectives 
The key findings of the ‘NK cell part’ of my PhD-thesis were that (i) blocking CD25 in 
vivo has a differential impact on NK cell-phenotype and -numbers in kidney transplant 
recipients vs. patients with autoimmune disease, and (ii) regulatory cytokine secretion 
can be induced in unprimed NK cells in a cell-cell contact dependent manner –both in 
autologous and allogeneic systems.  It is now interesting to speculate about the 
potential function of NK cells in solid organ transplant settings, from homing to secretion 
of immunoregulatory cytokines. 
Ad (i)  In kidney transplantation, efforts are made to match, in donor and recipient, the 
loci HLA A, HLA B and HLA DR.  However, it is the non-matched HLA C locus that is 
most involved in NK cell alloreactivity.1  In mice, there is evidence that NK cells 
influence the outcome of solid organ transplantation.  In CD28-/- mice, for instance, it 
was shown that cardiac allo-transplants were rejected via NK cell graft infiltrations and 
subsequent T cell stimulation.2,3  Also, it was shown that NK cells can home into the 
lymph nodes to stimulate the adaptive immune response, both via direct cell-cell contact 
with DCs4 and by providing an early source of IFN-γ upon activation.5  It will now be 
interesting to investigate the migration pattern of allo-specific NK cells.  Specifically, it 
would be interesting to establish the chemokine receptor expression-profile of allo-
specific NK cells in patients with differing grades of allo-graft specific immunity and 
differing HLA C matching/missmatching.6 
Ad (ii)  The molecular mechanism(s) leading to secretion by NK cells of the regulatory 
cytokine IL-10 are not clearly defined.  It has been shown that IL-12 and IL-15 can 
induce NK cells to secrete IL-10,7 and only recently it was observed that membrane-
bound IL-15 signals development of an IL-10 secreting regulatory NK cell subset.8,9  In 
our experiments, we show that –in a cell-cell contact-dependent manner– IL-10 is 
induced under autologous and allogeneic conditions in a small subset of unprimed NK 
cells.  The size of this population induced to secrete IL-10 was found to relate to the 
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HLA-C allotype of the allo-target population.  Since IL-10 was detected among the 
KIRdim/- NK cell subset, it is tempting to speculate that this regulatory response is 
mediated in a non-HLA dependent manner.  It will now be interesting to characterize the 
molecular mechanisms inducing NK cells to secrete IL-10, and whether this cytokine 
impacts development of alloreactivity. 
The key findings of the ‘CD8+ T cells part’ of my PhD-thesis were (i) that CCR7+ and 
CCR7- CD8+ T cells exhibit a distinct migration pattern when examined under 
conditions mimicking the interstitial vs. the extravascular milieu and (ii) that these same 
CD8+ T cell-subsets differentially regulate their heat production. 
Ad (i)  Intravital microscopy has been used quite extensively to study migration patterns 
of CD8+ T cells in mice.10,11  In these systems it has been shown that T cells screen for 
antigen while randomly migrating through lymph nodes –along anatomically defined 
pathways consisting of a network of fibroblastic reticular cells.12-14  The here established 
fact that CCR7- CD8+ T cells contain a higher frequency of crawling cells than their 
CCR7+ counterparts may indicate that cells screening for antigen in comparably ill-
organized interstitial tissues are forced to crawl more to detect antigen at the same rate 
than cells screening highly organized lymphoid tissues. 
Ad (ii)  From the literature it is known that immune responses most efficiently develop at 
a temperatures of 37°C, while developing sub-optimally when induced at lower 
temperatures.15,16  An exciting hypothesis –that we are currently testing– now states that 
induced (UCP-2 mediated) heat production by lymphnode homing T cells may raise the 
local (i.e. draining) lymph node-temperature to the level required for the best possible 
immune response to ensue. 
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